The Academy of Managed Care Pharmacy's (AMCP) 2006 Educational Conference begins at noon Oct. 4 at the Hyatt Regency, Chicago. Attendees from healthcare organizations, government agencies, academia and the pharmacy industry will be exploring the fast-changing issues driving pharmacy benefit design.
The Academy of Managed Care Pharmacy's (AMCP) 2006 Educational Conference begins at noon Oct. 4 at the Hyatt Regency, Chicago. Attendees from healthcare organizations, government agencies, academia, and the pharmacy industry will be exploring the fast-changing issues driving pharmacy benefit design.
Presentations, workshops, round-table discussions, and symposia by expert faculty from nationally respected healthcare, academic, and policy organizations will examine the issues and latest developments in Medicare legislation and pharmacy practice.
Keynote speakers will include David Brailer, MD, PhD, former national coordinator for Health Information Technology, U.S. Department of Health and Human Services, on Oct. 5, and Cokie Roberts, ABC News and NPR correspondent and author, on Oct. 6.
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
FDA Advisory Committee Votes Down Sotagliflozin in Type 1 Diabetes and CKD
November 1st 2024Committee members said there was uncertainty around sotagliflozin in patients with kidney disease. The FDA is currently reviewing the oral therapy as an adjunct to insulin to help control glycemic levels in adults with type 1 diabetes and chronic kidney disease. The agency’s goal date is Dec. 20, 2024.
Read More
ICER Gives Cell Therapy for Post-Transplant Complications High Rating
Published: October 31st 2024 | Updated: October 31st 2024ICER has given tabelecleucel a rating of A, indicating the T cell therapy for Epstein-Barr virus related post-transplant lymphoproliferative disease has a high certainty of substantial net health benefit and would be cost-effective if priced between $143,900 and $273,700.
Read More